A Phase I study of RG7112 (NCT00623870) in patients with hematologic malignancies has shown that RG7112 does not affect p53 transcription but can inhibit p53 degradation, thereby activating p53 target genes and promoting cell-cycle arrest and apoptosis in leukemia cells. This evidence concerns the gene TP53 and leukemia.